Business context and reporting period
The supplied filing is Ocuphire Pharma, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2022—not a filing by Opus Genetics, Inc., as specified in the request metadata. Ocuphire is a clinical-stage ophthalmic biopharmaceutical company with no approved products and no significant product revenue. Its lead candidates are Nyxol eye drops and APX3330; it also has licensed APX2009 and APX2014.
Financial results and liquidity
| Metric | Q1 2022 | Q1 2021 |
|---|---|---|
| Revenue | No significant revenue | No significant revenue |
| Research and development expense | $4.772 million | $3.482 million |
| General and administrative expense | $1.736 million | $1.704 million |
| Total operating expenses / operating loss | $6.508 million | $5.186 million |
| Net loss | $6.595 million | $39.014 million |
| Operating cash used | $6.170 million | $5.812 million |
| Cash and cash equivalents, at period end | $19.246 million | $10.597 million |
Margins are not meaningful because the company had no significant revenue. Other key March 31, 2022 balances: total assets $20.485 million; total liabilities $3.213 million; stockholders’ equity $17.272 million; current liabilities $3.213 million; short-term loan $0.215 million. Cash and cash equivalents declined from $24.534 million at December 31, 2021. The company reported no investing cash flows and $0.882 million of net financing cash flows in Q1 2022, including $1.208 million gross ATM proceeds, partly offset by loan repayments and issuance costs.
Material changes versus the prior comparable period
- R&D expense rose $1.290 million, primarily due to increased Nyxol and APX3330 clinical-trial and manufacturing activity and other development work. G&A rose $32,000.
- Net loss narrowed substantially from $39.014 million to $6.595 million, principally because Q1 2021 included a $33.829 million noncash warrant-liability fair-value expense. The Series A warrants were reclassified to equity in 2021 and are no longer remeasured.
- Operating cash use increased $358,000 year over year. The 2022 quarter included $1.208 million of ATM share-sale proceeds; 336,544 shares were sold under the program.
Outlook, risks and unusual items
- Management estimated that cash on hand would fund operations into the second quarter of 2023. The filing nevertheless states that substantial doubt exists about the company’s ability to continue as a going concern; continued operations depend on obtaining additional financing, with no assurance it will be available. The company expects to fund operations through equity or debt financing, collaborations, partnerships, or licensing.
- Management expects losses and expenses to continue and R&D costs to increase as clinical programs advance. Additional financing may dilute shareholders; failure to obtain funding could require delaying, reducing, or ending development programs.
- Nyxol’s second Phase 3 RM trial, MIRA-3, reported positive topline results in March 2022; the company expected LYNX-1 Phase 3 night-vision-disturbance results in Q2 2022. Subject to successful and timely RM trials, it anticipated filing an NDA in late 2022. APX3330’s 103-patient ZETA-1 Phase 2b trial completed enrollment in March 2022, with topline results expected in the second half of 2022. These are forward-looking expectations, not reported outcomes for the quarter.
- COVID-19 could disrupt trials, manufacturing, supply chains, and financing. The company reported no material change to previously disclosed risk factors and no legal proceeding it considered likely to have a material adverse effect.
- Potential obligations include up to $11 million in development and regulatory milestones and up to $20 million in sales milestones under the Apexian sublicense, plus single-digit royalties on covered product sales; none were triggered or considered probable at March 31, 2022. The company also has a facility lease through December 31, 2022.
- After quarter-end, a director entered a consulting agreement effective April 1, 2022, providing $10,000 monthly cash compensation and a 50,000-option grant.
Important facts for investors to verify
- Confirm issuer identity: the supplied document is Ocuphire Pharma’s 10-Q, not an Opus Genetics filing.
- Track cash burn, remaining ATM capacity and share issuance, and whether financing extends beyond the stated Q2 2023 runway.
- Verify the outcomes and timing of the anticipated Nyxol and APX3330 clinical and regulatory milestones.
- Review potential dilution from outstanding warrants and options, and monitor milestone, royalty, and other contractual obligations.
- Assess the going-concern uncertainty and possible effects of COVID-19 or clinical delays on liquidity and development plans.